articleThe Lancet OncologyApr 17, 2013Closed access

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Royal Marsden NHS Foundation Trust · Royal Surrey County Hospital · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

728
total citations
FWCI
63.28
Percentile
100%
References
36
Citations per year

Authors

20

Topics & keywords

Keywords
  • Medicine
  • Capecitabine
  • Panitumumab
  • Epirubicin
  • Oxaliplatin
  • Internal medicine
  • Clinical endpoint
  • Population
UN Sustainable Development Goals
  • No poverty
No related works found for this paper.

Funding